LXRX vs. GERN

In the year-to-date period, LXRX achieves a -14.69% return, which is significantly higher than GERN's -66.10% return. Over the past 10 years, LXRX has underperformed GERN with an annualized return of -21.54%, while GERN has yielded a comparatively higher -11.12% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current LXRX Sharpe Ratio is -0.50, which is higher than the GERN Sharpe Ratio of -1.04. The chart below compares the historical Sharpe Ratios of LXRX and GERN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither LXRX nor GERN has paid dividends to shareholders.

The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum GERN drawdown of -98.65%. Use the drawdown chart below to compare losses from any high point for LXRX and GERN. For additional features, visit the drawdowns tool.

Lexicon Pharmaceuticals, Inc. (LXRX) has a higher volatility of 26.12% compared to Geron Corporation (GERN) at 19.46%. This indicates that LXRX's price experiences larger fluctuations and is considered to be riskier than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Lexicon Pharmaceuticals, Inc. and Geron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.